The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Touchstone Innovations Plc

12 Sep 2017 11:50

RNS Number : 5174Q
Baillie Gifford & Co.
12 September 2017
 

 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Baillie Gifford & Co

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Touchstone Innovations Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

11 September 2017

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

3 1/33p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,744,564

1.70%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

 

2,744,564

 

1.70%

\* The change in the interest of 384,196 shares since the last disclosure on 25 July 2017 is due to the transfer out of a discretionary interest.

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

3 1/33p ordinary

Sale

52,633

GBP 2.46

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None.

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None.

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

12 September 2017

Contact name:

Grant Meikle

Telephone number:

0131 275 3134

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

 The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETDMGMLGZLGNZM
Date   Source Headline
12th Dec 20123:02 pmRNSResult of AGM
16th Nov 20127:00 amRNSVeryan CE Mark approval for BioMimics 3D Stent
5th Nov 20127:00 amRNSPortfolio companies receive government funding
19th Oct 201210:00 amRNSGrant of share options
5th Oct 20127:00 amRNSFull year results
4th Oct 20127:00 amRNSCircassia initiates phase III trial
26th Sep 20127:00 amRNSPsiOxus commences clinical trial
20th Sep 201212:39 pmRNSNotice of Results
13th Sep 20123:25 pmRNSCircassia appoints Dr Brett Haumann as CMO
12th Sep 201211:35 amRNSAward Win
6th Sep 20127:00 amRNSInvestment in Cambridge technology company
1st Aug 20123:58 pmRNSDirector Dealings
23rd Jul 20127:00 amRNSInvestment in portfolio company
11th Jul 20122:50 pmRNSVeryan Medical appoints new COO and NEDs
9th Jul 20127:00 amRNS£22m funding round for PsiOxus Therapeutics
5th Jul 20125:20 pmRNSGrant of share options
27th Jun 20128:12 amRNSAbingdon Health acquires controlling stake
18th Jun 20127:00 amRNSInvestment in Oxford healthcare company
12th Jun 20127:00 amRNSInvestment in Cambridge technology company
31st May 20129:36 amRNSDirector/PDMR Shareholding
29th May 201210:05 amRNSPolytherics expands relationship with Pro Bono Bio
24th May 20127:00 amRNSDirector Dealings
1st May 20123:04 pmRNSDirector Dealings
23rd Apr 20127:00 amRNSHalf year results
26th Mar 20123:51 pmRNSNotice of Results
26th Mar 20127:00 amRNSInvestment in portfolio company
21st Mar 20127:00 amRNSDirectorate Change
8th Mar 20127:00 amRNSCircassia Phase II Clinical Trial Success
13th Feb 20127:00 amRNSInvestment in portfolio company
14th Dec 20115:27 pmRNSResult of AGM
6th Dec 20117:00 amRNSInvestment in new start-up
5th Oct 20117:00 amRNSFinal Results
27th Sep 20118:56 amRNSNotice of Results
7th Sep 20117:00 amRNSFurther investment in portfolio company
25th Aug 20117:00 amRNSInvestment in Cambridge company
22nd Aug 20117:00 amRNSInvestment in new company
3rd Aug 20117:00 amRNSInvestment in portfolio company
20th Jul 20117:00 amRNSInvestment in Stanmore
22nd Jun 20119:35 amRNSPortfolio company joint venture
19th Apr 20117:00 amRNSCircassia raises £60m
19th Apr 20117:00 amRNSHalf Yearly Report
30th Mar 201112:41 pmRNSNotice of Results
7th Feb 20116:00 pmRNSNotification of major interest in shares
3rd Feb 20118:16 amRNSDirectors' Dealings
27th Jan 20112:56 pmRNSNotification of major interest in shares
27th Jan 20112:51 pmRNSNotification of major interest in shares
26th Jan 20116:01 pmRNSNotification of major interest in shares
25th Jan 20116:03 pmRNSDirectors' Dealings
25th Jan 20115:40 pmRNSResults of Rump placing
24th Jan 20114:11 pmRNSVoting rights & share capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.